Dose-finding Trial of HCD122 in Patients With Chronic Lymphocytic Leukemia (CLL) That is Relapsed or Non-responsive to Prior Fludaribine Therapy
The purpose of this study is to determine the highest tolerated dose, safety and activity of HCD122 in patients with chronic lymphocytic leukemia who are relapsed after receiving prior treatment.
Chronic Lymphocytic Leukemia
DRUG: HCD122
to determine the maximum tolerated dose (MTD), between study Day 1 and study Day 50
to characterize safety and tolerability of HCD122 at each dose level in dose escalation patients, between study Day 1 and study termination|To characterize pharmacokinetics of HCD122 at each dose level in dose escalation patients, between study Day 1 and study termination|To characterize peripheral blood CD40 occupancy on CD5/CD19 (CLL) cells and CD5/CD19 cell depletion activity (pharmacodynamics) of HCD122 at each dose level in dose escalation patients, between study Day 1 and study termination|To assess preliminary anti-tumor activity of HCD122 in dose escalation patients, between study Day 1 and study termination
The purpose of this study is to determine the highest tolerated dose, safety and activity of HCD122 in patients with chronic lymphocytic leukemia who are relapsed after receiving prior treatment.